The study, published in Supportive Care in Cancer by a research team led by Jinting Sun and colleagues at the First Affiliated Hospital of Soochow University in Suzhou, set out to understand why early screening behavior for BCRL varies so widely among survivors. Rather than measuring screening rates numerically, the researchers took a qualitative descriptive approach, conducting semi-structured interviews with 20 postoperative breast cancer patients recruited from a tertiary hospital. They used purposive sampling with maximum variation to ensure the participants reflected a range of ages, treatment experiences, and backgrounds, and they analyzed the transcripts using the six-phase thematic analysis procedure developed by Braun and Clarke, with reporting that followed the COREQ guidelines for qualitative research. The goal was not to count barriers but to understand them from the inside, through the words and reasoning of the patients themselves.

To organize their inquiry, the team anchored the study in the health belief model, a classic framework in health psychology first articulated in the 1950s and later refined by Janz and Becker. The model proposes that whether a person adopts a preventive health behavior depends on several cognitive appraisals: their perceived susceptibility to the condition, their perception of its severity, their belief in the benefits of taking action, their assessment of the barriers to action, and the internal cues and self-efficacy that drive them to act. Applied to BCRL, the model asks a deceptively simple question: if screening can prevent a debilitating complication, why do so many survivors not show up for it? The answers that emerged from the Suzhou interviews were layered and, in places, unexpected.

The first major theme the researchers identified was limited understanding and misinterpretation of BCRL risk. Many participants simply did not know what lymphedema was, had never heard the term before their surgery, or confused it with ordinary postoperative swelling that resolves on its own. Some underestimated their personal risk, assuming that lymphedema was something that happened to other people, or that their own treatment had been mild enough to spare them. This pattern of unrealistic optimism is well documented in the screening literature; earlier work on Israeli women’s screening intentions by Barnoy and colleagues showed how perceived control and optimism can suppress preventive behavior. In the Suzhou cohort, limited awareness of the long-term consequences of lymphedema—including its chronicity, its cosmetic and functional impact, and its links to psychological distress and even sleep problems—further weakened any sense of urgency. When a threat feels vague and distant, the cognitive machinery that motivates prevention rarely engages.

The second theme captured the motivations and barriers to screening behavior themselves. Participants who did attend screening often did so because they perceived concrete benefits: the possibility of catching swelling early, receiving timely guidance on arm care, and avoiding the heavier costs of late-stage treatment. But these perceived benefits competed against a formidable array of barriers. Some patients expressed skepticism about whether screening actually worked or whether early detection changed outcomes at all. Others described logistical hurdles—travel time, appointment scheduling, out-of-pocket costs, and the sheer fatigue of recovering from cancer treatment while juggling family and work obligations. The health belief model predicts exactly this tension: behavior emerges only when perceived benefits outweigh perceived barriers, and for many survivors in this study, the balance tipped away from screening.

The third theme broadened the lens from individual cognition to social and systemic constraints. Screening behavior, the interviews made clear, does not happen in a vacuum. Participants described family dynamics that shaped whether they could prioritize their own follow-up care, with some women deprioritizing their health in favor of caregiving responsibilities. They also pointed to gaps in the healthcare system itself: limited survivorship follow-up structures, inconsistent communication from clinicians about lymphedema risk, and scarce access to specialized screening services such as bioimpedance spectroscopy, which clinical practice guidelines, including the 2024 MASCC international Delphi consensus recommendations, identify as a valuable tool for detecting subclinical lymphedema. This systemic dimension echoes broader findings in the literature; a 2025 systematic review by Mattia and colleagues documented persistent inequities and barriers in lymphedema care, and a 2024 study in a safety-net hospital by Young and colleagues found substantial screening and treatment gaps even within well-resourced health systems.

The fourth and perhaps most hopeful theme concerned self-efficacy and health responsibility. Even among patients facing real obstacles, some had internalized a sense of ownership over their long-term health. These participants described screening not as an imposition but as an expression of responsibility to themselves and their families, and they reported confidence in their ability to carry out the recommended behaviors. This aligns with cross-sectional evidence from Chinese women showing that self-efficacy mediates the relationship between social support and cancer screening behavior, as reported by Tu and colleagues in 2024. In the health belief model’s terms, self-efficacy functions as the engine that converts awareness into action; without it, even well-informed patients may stall. The Suzhou findings suggest that cultivating this internalized health responsibility may be as important as delivering information.

Taken together, the four themes paint a picture of screening behavior as an interaction between cognitive appraisal, contextual constraints, and health system factors. No single lever—patient education alone, or clinic access alone—will move the needle. The authors conclude that interventions should focus on strengthening survivorship follow-up, improving clinician communication about lymphedema risk, and expanding access to screening services. In practical terms, this could mean embedding lymphedema education into routine postoperative consultations, providing clear risk information tailored to each patient’s treatment profile, and building screening into standard follow-up pathways rather than leaving it as an optional extra that patients must seek out on their own initiative.

The stakes are considerable. Breast cancer remains the most commonly diagnosed cancer among women globally, with GLOBOCAN 2022 estimates documenting its enormous and growing burden. As survival improves, the population living with treatment sequelae expands in parallel, and the cumulative economic burden of lymphedema treatment—documented in a systematic review by De Vrieze and colleagues—is substantial for both patients and health systems. Risk prediction models for BCRL, reviewed by Lin and colleagues, are becoming more sophisticated, and diagnostic tools such as bioimpedance spectroscopy now have dedicated clinical practice guidelines. The science of detection is advancing; the science of getting patients through the door is lagging behind, and this study helps explain why.

What makes the Suzhou study valuable is precisely its refusal to treat non-screening as simple negligence. The interviews reveal rational patients making decisions within constrained circumstances, shaped by incomplete information, competing priorities, skepticism, and system-level friction. For clinicians, the message is that communication must do more than inform; it must build perceived susceptibility without inducing fatalism, demonstrate the tangible benefits of early detection, and lower the practical barriers that stand between intention and action. For policymakers, the message is that survivorship care pathways need structural reinforcement so that screening becomes the default rather than the exception. And for survivors themselves, the study is a reminder that a feeling of well-being in the months after surgery is not a guarantee of freedom from lymphedema, and that a simple, early check may be one of the most consequential health decisions of the survivorship journey.

Subject of Research: Factors influencing early screening behavior for breast cancer–related lymphedema among postoperative breast cancer patients, analyzed through the health belief model

Article Title: Based on the health belief model: a qualitative exploration of factors influencing early screening behavior for breast cancer–related lymphedema

Article References: Based on the health belief model: a qualitative exploration of factors influencing early screening behavior for breast cancer–related lymphedema. (n.d.). https://doi.org/10.1007/s00520-026-11219-3

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11219-3

Keywords: breast cancer-related lymphedema, screening behavior, health belief model, qualitative research, self-efficacy, cancer survivors, perceived susceptibility, health barriers, survivorship care, bioimpedance spectroscopy, patient education, China